2-氟-6-碘苯甲酸 | 111771-08-5

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氟-6-碘苯甲酸
• 英文名称: 2-fluoro-6-iodobenzoic acid
• 英文别名: 2-iodo-6-fluorobenzoic acid；6-fluoro-2-iodobenzoic acid
• CAS: 111771-08-5
• 化学式: C₇H₄FIO₂
• mdl: MFCD00042289
• 分子量: 266.01
• InChiKey: CYCXAPWOBWWNRK-UHFFFAOYSA-N

物化性质

• 熔点：
  123-126 °C (lit.)
• 沸点：
  301.6±27.0 °C(Predicted)
• 密度：
  1.9575 (estimate)
• 溶解度：
  溶于甲醇
• 稳定性/保质期：
  在常温常压下保持稳定，应避免与强氧化剂和强碱接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2916399090
• 危险标志：
  GHS07
• 危险性描述：
  H315,H319,H335
• 危险性防范说明：
  P261,P305 + P351 + P338
• 储存条件：
  密封保存，应储存在阴凉干燥的仓库中。

SDS

Name:	2-Fluoro-6-iodobenzoic acid 98% Material Safety Data Sheet
Synonym:	None
CAS:	111771-08-5

Section 1 - Chemical Product MSDS Name:2-Fluoro-6-iodobenzoic acid 98% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
111771-08-5	2-Fluoro-6-iodobenzoic acid	98.0	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
May cause irritation of the digestive tract. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Causes irritation of mucous membrane.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Antidote: None reported.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Clean up spills immediately, observing precautions in the Protective Equipment section. Sweep up or absorb material, then place into a suitable clean, dry, closed container for disposal. Avoid generating dusty conditions. Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 111771-08-5: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 123 - 126 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H4FIO2
Molecular Weight: 266.01

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials, dust generation.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, hydrogen fluoride gas, hydrogen iodide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 111771-08-5 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Fluoro-6-iodobenzoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 37/39 Wear suitable gloves and eye/face
protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 111771-08-5: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 111771-08-5 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 111771-08-5 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

制备方法

化学试剂的制备方法未详细说明。

用途简介

用途简介内容为空。

用途

该化学试剂主要用于化学实验或相关研究。

反应信息

• 作为反应物：
  描述：

  2-氟-6-碘苯甲酸 在 copper(l) iodide 、 氯化亚砜 、 (1R,2R)-(-)-N,N'-二甲基-1,2-环己二胺 、 sodium carbonate 、 caesium carbonate 、 N,N-二甲基甲酰胺 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 水 、 甲苯 为溶剂， 反应 6.75h， 生成 (5-(4,6-二甲基嘧啶-2-基)六氢吡咯并[3,4-C]吡咯-2(1H)-基)(2-氟-6-(2H-1,2,3-三唑-2-基)苯基)甲酮
  参考文献：
  名称：

  [EN] DISUBSTITUTED OCTAHY-DROPYRROLO [3,4-C] PYRROLES AS OREXIN RECEPTOR MODULATORS
  [FR] OCTAHYDROPYRROLO [3,4-C] PYRROLES DISUBSTITUÉS UTILISÉS COMME MODULATEURS DU RÉCEPTEUR DE L'OREXINE

  摘要：

  描述了二取代的八氢吡咯[3,4-c]吡咯化合物，这些化合物可用作促进睡眠素受体的调节剂。这些化合物可能在药物组合物和治疗由促进睡眠素活性介导的疾病状态、紊乱和病况的方法中有用，比如失眠。

  公开号：

  WO2012145581A1
• 作为产物：
  描述：

  邻氟苯甲酸 在 N-碘代丁二酰亚胺 、 [Ir(III)(η5-pentamethylcyclopentadienyl)(H2O)3](SO4) 作用下， 反应 16.0h， 以74%的产率得到2-氟-6-碘苯甲酸
  参考文献：
  名称：

  苯甲酸的无碱和无添加剂Ir催化邻位碘化：范围和机理研究

  摘要：

  已经开发了一种由简单铱络合物催化的苯甲酸的C–H活化/碘化的方案。本文描述的方法允许在非常温和的条件下，在没有任何添加剂或碱的情况下，在1,1,1,3,3,3-六氟异丙醇作为溶剂中对多种苯甲酸进行邻位碘化。所用的铱催化剂可耐受空气和湿气，并选择性地以高转化率得到邻碘苯甲酸。机理研究表明，Ir（III）/ Ir（V）催化循环起作用，并且HFIP的独特性质使得能够使用羧基作为引导基团进行C-H碘化。

  DOI：

  10.1021/acscatal.7b02987

文献信息

• [EN] SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE 2-AZABICYCLO[3.1.1]HEPTANE ET DE 2-AZABICYCLO[3.2.1]OCTANE SUBSTITUÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'OREXINE
  申请人：CHRONOS THERAPEUTICS LTD

  公开号：WO2019043407A1

  公开（公告）日：2019-03-07

  There is provided a compound of formula (I), wherein L1 to L3, R1 to R4, X, A and B have meanings given in the description, and pharmaceutically acceptable salts, solvates and prodrugs thereof, which compounds are useful as antagonists of the orexin-1 and orexin-2 receptors or as selective antagonists of the orexin-1 receptor, and thus, in particular, in the treatment or prevention of inter alia substance dependence, addiction, anxiety disorders, panic disorders, binge eating, compulsive disorders, impulse control disorders, cognitive impairment and Alzheimer's disease.

  提供一种化合物，其化学式为（I），其中L1至L3，R1至R4，X，A和B的含义如描述中所给，并且其药学上可接受的盐、溶剂合物和前药，这些化合物可用作促进睡眠素-1和促进睡眠素-2受体的拮抗剂或作为促进睡眠素-1受体的选择性拮抗剂，因此，特别适用于治疗或预防物质依赖、成瘾、焦虑障碍、恐慌障碍、暴饮暴食、强迫障碍、冲动控制障碍、认知障碍和阿尔茨海默病等疾病。
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：ROTTAPHARM SPA

  公开号：WO2013092893A1

  公开（公告）日：2013-06-27

  The invention relates to a novel compound of formula (I) or a stereoisomer, or a racemate or a mixture or a pharmaceutically acceptable salt thereof: wherein: R is phenyl or a 5- or 6-membered heteroaryl ring containing 1 to 3 heteroatoms selected from S, N and O, such rings may be optionally substituted with n groups Q; Q is selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, SO2CH3 or a group -O[(CR1R2]pQ1; or Q may be a group Q2; Q1 is phenyl, which may be optionally substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN, or a group Q2; or corresponds to 2,2-difluoro- benzo[d][1,3]dioxol-4-yl; Q2 is a 5- or 6-membered heteroaryl containing at least one nitrogen atom, which may optionally substituted with n substituents selected from a group consisting of: C1 C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; P is a 6-membered heteroaryl or a 8-1 1 membered bicylic heteroaryl group, which may be substituted with n substituents selected from a group consisting of: C1-C4 alkyl, halogen, halo C1-C4 alkyl, C1-C4 alkoxy, CN; R1 is hydrogen or C1-C3 alkyl; R2 is hydrogen or C1-C3 alkyl; n is 1, 2 or 3; p is 0, 1 or 2; and with the proviso that when R corresponds to phenyl, P is substituted by at least one CF3; processes for the preparation of those compounds, pharmaceutical compositions containing one or more compounds of formula (I) and their use as dual antagonists of the Orexin 1 and Orexin 2 receptors.

  该发明涉及以下式(I)的新化合物或其立体异构体、消旋体或混合物或其药学上可接受的盐：其中：R为苯基或含有1至3个来自S、N和O的杂原子的5-或6-成员杂芳环，这些环可以选择性地用n个基团Q取代；Q选自以下组成的一组：C1-C4烷基、卤素、卤代C1-C4烷基、C1-C4烷氧基、CN、SO2CH3或一个基团-O[(CR1R2]pQ1；或Q可以是一个基团Q2；Q1为苯基，可以选择性地用n个取代基从以下组成的一组中取代：C1-C4烷基、卤素、卤代C1-C4烷基、C1-C4烷氧基、CN或一个基团Q2；或对应于2,2-二氟苯并[d][1,3]二噁唑-4-基；Q2为含有至少一个氮原子的5-或6-成员杂芳基，可以选择性地用n个取代基从以下组成的一组中取代：C1-C4烷基、卤素、卤代C1-C4烷基、C1-C4烷氧基、CN；P为6-成员杂芳基或8-11-成员双环杂芳基，可以选择性地用n个取代基从以下组成的一组中取代：C1-C4烷基、卤素、卤代C1-C4烷基、C1-C4烷氧基、CN；R1为氢或C1-C3烷基；R2为氢或C1-C3烷基；n为1、2或3；p为0、1或2；并且在R对应于苯基时，P至少被一个CF3取代；制备这些化合物的方法，含有一个或多个式(I)化合物的药物组合物以及它们作为Orexin 1和Orexin 2受体的双重拮抗剂的用途。
• Condensed pyrazole derivatives, process for producing the same and use thereof
  申请人：——

  公开号：US20030187014A1

  公开（公告）日：2003-10-02

  Novel pharmaceutical compositions for inhibiting Th2-selective immune response and pharmaceutical compositions for inhibiting cyclooxygenase comprising condensed pyrazole derivatives represented by the general formula (I): 1 or salts thereof.

  用于抑制Th2选择性免疫应答的新型药物组合物和包括由一般式(I)表示的紧缩吡唑烷衍生物的药物组合物，或其盐。
• Free radical reactions for heterocycle synthesis. Part 7: 2-Bromobenzoic acids as building blocks in the construction of spirobenzolactones and spirobenzolactams
  作者：Wei Zhang、Georgia Pugh

  DOI：10.1016/s0040-4020(03)00655-0

  日期：2003.6

  A straightforward 2-step parallel synthesis for structurally diversified spiro compounds is developed. 2-Bromobenzoic acids are used as common building blocks to couple with a series of conjugated enoles or enamines. Sequential intramolecular free radical Michael additions lead to formation of spirobenzolactones, spirobenzolactams, spirobenzolactone-lactams, spiorbenzolactone-thiolactones, spiordilactones

  开发了一种简单的两步平行合成方法，用于结构上多样化的螺环化合物。2-溴苯甲酸用作常见的结构单元，与一系列共轭的烯醇或烯胺偶联。依次的分子内自由基迈克尔加成导致形成螺苯并内酯，螺苯并内酰胺，螺苯并内酯-内酰胺，螺苯并内酯-硫代内酯，螺二内酯和桥连螺内酯。
• Palladium-catalyzed intermolecular tandem cyclization reaction: a highly regioselective synthesis of functionalized 3H-spiro[isobenzofuran-1,3′-isochroman] scaffolds
  作者：Liang Wang、Xuehu Li、Hua Tao、Xiang Zhou、Xihong Lu、Wenyue Du、Tingting Jiang、Zhijun Xin、Jianping Liang

  DOI：10.1039/c6ob02802k

  日期：——

  functionalized 3H-spiro[isobenzofuran-1,3′-isochroman] scaffolds using a novel palladium-catalyzed tandem cyclization reaction is explored. During the reaction process, C–O, C–C and C–O bonds are sequentially formed in one pot via decarboxylative allenylpalladium formation, nucleophilic attack, arylpalladium addition and intramolecular nucleophilic attack.

  探索了使用新型钯催化串联环化反应的功能性3 H-螺[异苯并呋喃-1,3'-异色满]支架的高度区域选择性合成。在反应过程中，通过脱羧化烯基钯的形成，亲核攻击，芳基钯加成和分子内亲核攻击，在一个罐中依次形成C–O ，CC和C–O键。

表征谱图